Johnson & Johnson Stock Price, News & Analysis

Johnson & Johnson (NYSE:JNJ) has received FDA approval for INLEXZO™, a groundbreaking bladder cancer treatment. This first-of-its-kind intravesical drug releasing system (iDRS) provides extended local delivery of gemcitabine for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

The SunRISe-1 Phase 2b clinical study demonstrated remarkable efficacy, with 82% of patients achieving complete response and 51% maintaining response for at least one year. INLEXZO™ remains in the bladder for three weeks per treatment cycle for up to 14 cycles, offering a bladder-preserving alternative to surgery.

The FDA granted INLEXZO™ Breakthrough Therapy Designation, Real-Time Oncology Review, and Priority Review. J&J will support patient access through their J&J withMe program, providing cost support and resources.

Johnson & Johnson (NYSE: JNJ) has announced the election of John Morikis, the retired Chairman, President and CEO of The Sherwin-Williams Company, to its Board of Directors. Morikis brings extensive experience in leading multinational organizations and deep understanding of global markets and complex supply chains.

According to Chairman and CEO Joaquin Duato, Morikis's expertise in leveraging technology for innovation will support J&J's mission to advance healthcare innovation. Morikis expressed his enthusiasm about joining the board and contributing to the company's strategy of developing breakthrough treatments while creating shareholder value.

Johnson & Johnson (NYSE: JNJ) announced its participation in the upcoming Bernstein 2nd Annual Healthcare Forum. The company's management will engage in a Fireside Chat on September 24th, 2025, at 1:10 p.m. Eastern Time.

Investors can access a live audio webcast of the presentation through the company's Investor Relations website. An archived version will be available approximately 48 hours after the event.

Johnson & Johnson (NYSE: JNJ) announced groundbreaking results from the Phase 3 MARIPOSA study published in The New England Journal of Medicine. The study evaluated RYBREVANT® plus LAZCLUZE® for first-line treatment of EGFR-mutated non-small cell lung cancer.

The combination therapy demonstrated statistically significant improvement in overall survival compared to osimertinib, with a projected survival exceeding four years - more than one year longer than the current standard of care. At 37.8 months median follow-up, the treatment showed a significant reduction in death risk (HR: 0.75, P=0.005).

The drug combination's triple mode of action targets EGFR mutations, blocks MET, and engages the immune system, potentially changing the disease's natural progression by reducing resistance mechanisms. The safety profile remained consistent with previous analyses, with most adverse events occurring early in treatment.

Johnson & Johnson (NYSE:JNJ) announced significant new analyses from the Phase 3 MARIPOSA study for RYBREVANT® plus LAZCLUZE® in treating EGFR-mutated non-small cell lung cancer (NSCLC). The combination therapy showed remarkable results in preventing resistance mutations compared to osimertinib treatment.

Key findings demonstrate that MET amplifications occurred in only 3% of combination therapy patients versus 13% with osimertinib, while secondary EGFR mutations were significantly lower (1% vs 8%). The combination therapy extends survival with a projected benefit exceeding four years, representing a one-year improvement over osimertinib alone.

The treatment is now approved in the United States, Europe, and other markets for first-line EGFR-mutated NSCLC based on the MARIPOSA study results. The safety profile remained consistent with previous analyses, with most adverse events occurring early in treatment.

Johnson & Johnson (NYSE: JNJ) has scheduled its third-quarter earnings conference call for October 14th, 2025, at 8:30 a.m. ET. The call will be hosted by key executives including CEO Joaquin Duato, CFO Joseph J. Wolk, and VP of Investor Relations Darren Snellgrove.

The earnings press release will be available at 6:45 a.m. ET on the same day. Investors can access the call via webcast at www.investor.jnj.com or by telephone. U.S. participants can dial 877-869-3847, while international participants should use 201-689-8261. A replay will be available until October 28th.

Johnson & Johnson (NYSE:JNJ) has announced significant results from the VARIPURE substudy of SECURE, evaluating their VARIPULSE™ Platform for atrial fibrillation treatment. The study, conducted across 20 European centers with 791 patients, demonstrated remarkable safety and effectiveness metrics.

Key findings include a 0.6% primary adverse event rate with no strokes reported, and a 99.7% acute effectiveness rate in pulmonary vein isolation (PVI). The study involved 62 operators and evaluated acute safety, effectiveness, and procedural characteristics of index AF ablations. Additional supporting data from the REAL AF Registry across 70 US and Canadian sites showed no strokes, deaths, or device-related hospitalizations in 200 diverse clinical profiles.

Johnson & Johnson (NYSE:JNJ) announced groundbreaking long-term data from the DanGer Shock randomized controlled trial for its Impella CP heart pump, published in The New England Journal of Medicine and presented at the European Society of Cardiology Congress.

The study demonstrated that Impella CP achieved an absolute mortality reduction of 16.3% over 10 years compared to standard care, with patients gaining an average of 600 additional days of life. This improvement surpasses the initial 6-month data, which showed a 12.7% reduction in mortality.

The trial, which enrolled 360 participants across 14 sites in Denmark, Germany, and the UK, led to the American College of Cardiology and American Heart Association upgrading Impella to a class 2a guideline recommendation. This marks Impella CP as the first mechanical circulatory support device proven to provide both short-term and long-term survival benefits in STEMI-related cardiogenic shock patients.

Johnson & Johnson's (NYSE:JNJ) Biosense Webster unit has been hit with a permanent injunction by the U.S. District Court for Central California following antitrust violations. The ruling follows a jury verdict that awarded $442 million in damages to Innovative Health, LLC.

The court order prohibits BSW from several anti-competitive practices, including: tying clinical support to exclusive device purchases, discriminating in service provision, implementing anti-reprocessing technologies, and hoarding used catheters. The five-year injunction aims to protect hospitals' access to FDA-regulated reprocessed cardiac catheters, promoting cost savings and environmental sustainability.